ARS Pharmaceuticals, Inc. (SPRY) Return on equity 2022–2025
ARS Pharmaceuticals, Inc. (SPRY) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-149.9%FY2025 · since FY2022: -12.7% → -149.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -149.9% | -153.0 pp |
| FY2024 | 3.1% | +26.7 pp |
| FY2023 | -23.6% | -10.8 pp |
| FY2022 | -12.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice